Current advancements in promoting remyelination in multiple sclerosis.
Multiple sclerosis
myelin repair
oligodendroglia
therapy
trials
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
3
10
2018
medline:
16
1
2020
entrez:
2
10
2018
Statut:
ppublish
Résumé
Current multiple sclerosis (MS) therapies are effective in reducing relapse rate, short-term measures of disability, and magnetic resonance imaging (MRI) measures of inflammation in relapsing remitting MS (RRMS), whereas in progressive/degenerative disease phases these medications are of little or no benefit. Therefore, the development of new therapies aimed at reversing neurodegeneration is of great interest. Remyelination, which is usually a spontaneous endogenous process, is achieved when myelin-producing oligodendrocytes are generated from oligodendrocyte precursor cells (OPCs). Even though these precursor cells are abundant in MS brains, their regeneration capacity is limited. Enhancing the generation of myelin-producing cells is therefore a major focus of MS research. Here we present an overview of the different advancements in the field of remyelination, including suitable animal models for testing remyelination therapies, approved medications with a proposed role in regeneration, myelin repair treatments under investigation in clinical trials, as well as future therapeutics aimed at facilitating myelin repair.
Identifiants
pubmed: 30270725
doi: 10.1177/1352458518800827
pmc: PMC6389436
mid: NIHMS1505010
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-14Subventions
Organisme : NINDS NIH HHS
ID : R01 NS096148
Pays : United States
Références
J Neurol Sci. 1982 Nov-Dec;57(1):105-10
pubmed: 7153781
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
Neuropharmacology. 2016 Nov;110(Pt B):644-653
pubmed: 26327679
CNS Drugs. 2013 Jul;27(7):493-503
pubmed: 23681979
Lancet Neurol. 2014 Mar;13(3):247-56
pubmed: 24461574
Nat Med. 2014 Aug;20(8):954-960
pubmed: 24997607
Exp Neurol. 2010 Sep;225(1):18-23
pubmed: 20044992
Nat Rev Neurol. 2012 Nov 5;8(11):624-34
pubmed: 23026979
Development. 2006 Nov;133(21):4219-31
pubmed: 17021034
J Neuroimmunol. 2006 Aug;177(1-2):99-111
pubmed: 16781782
Ann Neurol. 2013 Nov;74(5):721-32
pubmed: 23836485
FEBS Lett. 2011 Dec 1;585(23):3829-35
pubmed: 21420960
J Immunol. 2004 Jan 15;172(2):1246-55
pubmed: 14707103
Neurology. 2002 Oct 8;59(7):990-7
pubmed: 12370451
Endocrinol Jpn. 1980 Aug;27(4):521-5
pubmed: 7460861
Am J Pathol. 2010 Jun;176(6):2682-94
pubmed: 20413685
J Neurosci. 2007 Feb 21;27(8):1812-23
pubmed: 17314279
Lancet. 2014 Jun 28;383(9936):2213-21
pubmed: 24655729
Clin Rev Allergy Immunol. 2010 Aug;39(1):51-61
pubmed: 19697163
J Neurosci. 2016 Jul 27;36(30):7925-35
pubmed: 27466337
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
Ann Neurol. 1979 Jan;5(1):22-31
pubmed: 426466
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
J Neuroinflammation. 2016 Aug 26;13(1):207
pubmed: 27566665
Brain Pathol. 2001 Jan;11(1):107-16
pubmed: 11145196
Brain Res. 1987 Nov 3;425(1):186-90
pubmed: 3427420
Neurology. 2016 Mar 8;86(10):920-30
pubmed: 26865517
J Neuroimmunol. 2005 Dec 30;170(1-2):3-10
pubmed: 16290267
J Neurosci. 2014 Oct 15;34(42):14128-46
pubmed: 25319708
J Mol Med (Berl). 1997 Feb;75(2):77-88
pubmed: 9083925
Nat Rev Neurosci. 2010 Apr;11(4):275-83
pubmed: 20216548
J Vis Exp. 2015 Mar 26;(97):
pubmed: 25867716
J Neurocytol. 1972 Dec;1(4):413-26
pubmed: 8530973
J Neurosci. 2003 Oct 8;23(27):9229-39
pubmed: 14534257
N Engl J Med. 2017 Apr 27;376(17):1694
pubmed: 28445663
Annu Rev Neurosci. 2011;34:21-43
pubmed: 21692657
N Engl J Med. 2002 Jan 17;346(3):165-73
pubmed: 11796850
Curr Top Microbiol Immunol. 2005;296:39-53
pubmed: 16323419
J Neurosci Res. 2018 Jun;96(6):1021-1042
pubmed: 29446144
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769
pubmed: 29142295
Curr Alzheimer Res. 2014 Jan;11(1):47-58
pubmed: 24359500
J Neurosci. 2000 Sep 1;20(17):6404-12
pubmed: 10964946
J Neurol Sci. 2008 Feb 15;265(1-2):26-31
pubmed: 17961598
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
J Clin Invest. 2011 Dec;121(12):4722-34
pubmed: 22056384
J Neuroinflammation. 2018 Mar 13;15(1):76
pubmed: 29534752
Mult Scler. 2015 Apr;21(5):541-9
pubmed: 25623245
Nature. 2002 Oct 10;419(6907):629-33
pubmed: 12374982
Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S90-4
pubmed: 24321165
J Immunol. 2010 Feb 1;184(3):1499-506
pubmed: 20038643
N Engl J Med. 2017 Apr 27;376(17):1694
pubmed: 28445661
Brain. 2011 Mar;134(Pt 3):678-92
pubmed: 21354971
Ann Neurol. 2018 Jan;83(1):13-26
pubmed: 29244240
Ann Neurol. 2011 Apr;69(4):602-18
pubmed: 21520230
Lancet Neurol. 2017 Mar;16(3):189-199
pubmed: 28229892
Epigenetics. 2009 Jul 1;4(5):307-12
pubmed: 19633433
J Neurol. 2017 Feb;264(2):304-315
pubmed: 27888416
Nature. 2004 Jan 22;427(6972):355-60
pubmed: 14737169
Annu Rev Immunol. 1990;8:579-621
pubmed: 2188675
Lancet Neurol. 2011 Aug;10(8):691-701
pubmed: 21742556
Glia. 1999 Feb 1;25(3):216-28
pubmed: 9932868
Schizophr Res. 2015 May;164(1-3):136-42
pubmed: 25728831
Glia. 2007 Dec;55(16):1656-67
pubmed: 17876806
Glia. 2017 Dec;65(12):1900-1913
pubmed: 28836302
Nat Neurosci. 2011 Jan;14(1):45-53
pubmed: 21131950
J Neurochem. 2012 Oct;123(1):14-20
pubmed: 22817262
Am J Transl Res. 2016 Feb 15;8(2):1016-26
pubmed: 27158387
Nat Neurosci. 2005 Jan;8(1):34-42
pubmed: 15608632
J Virol. 2002 Dec;76(24):12834-44
pubmed: 12438608
Mult Scler. 2016 Nov;22(13):1719-1731
pubmed: 27589059
Nat Neurosci. 2005 Jun;8(6):745-51
pubmed: 15895088